1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Material Name: Levothyroxine Sodium Tablets

Trade Name: LEVOXYL
Chemical Family: Not determined
Intended Use: Pharmaceutical product

2. HAZARDS IDENTIFICATION

Appearance: Tablets, varying in color depending on strength

Statement of Hazard: Non-hazardous in accordance with international standards for workplace safety.

Additional Hazard Information:
- Long Term: Animal studies indicate that this material may cause adverse effects on the developing fetus.
- Known Clinical Effects: Clinical use of this drug has caused ventricular arrhythmia effects on the thyroid headache nervousness and sweating
- EU Indication of danger: Not classified


Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Levothyroxine sodium</td>
<td>55-03-8</td>
<td>200-221-4</td>
<td>Not Listed</td>
<td>25-200mg***</td>
</tr>
<tr>
<td>Magnesium Stearate</td>
<td>557-04-0</td>
<td>209-150-3</td>
<td>OEL</td>
<td>*</td>
</tr>
<tr>
<td>Microcrystalline cellulose</td>
<td>9004-34-6</td>
<td>232-674-9</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>
Additional Information:

* Proprietary
*** per tablet/capsule/lozenge/suppository
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

4. FIRST AID MEASURES

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Measures for Environmental Protections: Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.
7. HANDLING AND STORAGE

General Handling: Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Microcrystalline cellulose
- ACGIH Threshold Limit Value (TWA): 10 mg/m³
- Lithuania OEL - TWA: 5 mg/m³
- Sweden OEL - TWAs: 5 mg/m³

Magnesium Stearate
- ACGIH Threshold Limit Value (TWA): 10 mg/m³
- Australia TWA: 10 mg/m³
- Belgium OEL - TWA: 10 mg/m³
- Estonia OEL - TWA: 10 mg/m³
- France OEL - TWA: 10 mg/m³
- Ireland OEL - TWAs: 10 mg/m³
- Latvia OEL - TWA: 2 mg/m³
- OSHA - Final PELS - TWAs: 15 mg/m³
- Portugal OEL - TWA: 10 mg/m³
- Romania OEL - TWA: 10 mg/m³
- Spain OEL - TWA: 10 mg/m³

Levothyroxine sodium
- Pfizer Occupational Exposure Band (OEB): OEB 5 (control exposure to <1ug/m³)

Engineering Controls: Engineering controls should be used as the primary means to control exposures. Use process containment, local exhaust ventilation, or other engineering controls to maintain airborne levels within the OEB range. All operations should be fully enclosed. No air recirculation permitted.

Environmental Exposure Controls: Refer to specific Member State legislation for requirements under Community environmental legislation.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes: Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection: If airborne exposures are within or exceed the Occupational Exposure Band (OEB) range, wear an appropriate respirator with a protection factor sufficient to control exposures to the bottom of the OEB range.
9. PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Physical State:</th>
<th>Tablets</th>
<th>Color:</th>
<th>Various</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular Formula:</td>
<td>Mixture</td>
<td>Molecular Weight:</td>
<td>Mixture</td>
</tr>
</tbody>
</table>

10. STABILITY AND REACTIVITY

Chemical Stability: Stable under normal conditions of use.
Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

<table>
<thead>
<tr>
<th>Levothyroxine sodium</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
</tr>
<tr>
<td>Oral</td>
</tr>
<tr>
<td>LD50</td>
</tr>
<tr>
<td>&gt; 10000 mg/kg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Microcrystalline cellulose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
</tr>
<tr>
<td>Oral</td>
</tr>
<tr>
<td>LD50</td>
</tr>
<tr>
<td>&gt; 5000 mg/kg</td>
</tr>
<tr>
<td>Rabbit</td>
</tr>
<tr>
<td>Dermal</td>
</tr>
<tr>
<td>LD50</td>
</tr>
<tr>
<td>&gt; 2000 mg/kg</td>
</tr>
</tbody>
</table>

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

<table>
<thead>
<tr>
<th>Microcrystalline cellulose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin Irritation</td>
</tr>
<tr>
<td>Rabbit</td>
</tr>
<tr>
<td>Non-irritating</td>
</tr>
<tr>
<td>Eye Irritation</td>
</tr>
<tr>
<td>Rabbit</td>
</tr>
<tr>
<td>Non-irritating</td>
</tr>
</tbody>
</table>

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

<table>
<thead>
<tr>
<th>Magnesium Stearate</th>
</tr>
</thead>
<tbody>
<tr>
<td>13 Week(s) Rat Oral</td>
</tr>
<tr>
<td>1092 g/kg LOAEL Liver</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Levothyroxine sodium</th>
</tr>
</thead>
<tbody>
<tr>
<td>4 Week(s) Rat Oral</td>
</tr>
<tr>
<td>= 11.2 mg/kg LOAEL Endocrine system</td>
</tr>
<tr>
<td>5 Day(s) Rat Intraperitoneal</td>
</tr>
<tr>
<td>= 1000 mg/kg LOAEL Endocrine system, Blood</td>
</tr>
</tbody>
</table>

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.
13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Indication of danger: Not classified

EU Safety Phrases:

OSHA Label:
Non-hazardous in accordance with international standards for workplace safety.

Canada - WHMIS: Classifications

WHMIS hazard class:
None required

Levothyroxine sodium

Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
Standard for the Uniform Scheduling for Drugs and Poisons: Schedule 4
EU EINECS/ELINCS List 200-221-4

Magnesium Stearate
15. REGULATORY INFORMATION

| Inventory - United States TSCA - Sect. 8(b) | Present |
| Australia (AICS): | Present |
| EU EINECS/ELINCS List | 209-150-3 |

Crocarmellose sodium
- Australia (AICS): Present

Microcrystalline cellulose
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- EU EINECS/ELINCS List: 232-674-9

16. OTHER INFORMATION

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Prepared by: Product Stewardship Hazard Communication
- Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet